Journal of Chromatography B 2002-03-05

Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma.

Xiaoyan Chen, Dafang Zhong, Haiyan Xu, Barbara Schug, Henning Blume

Index: J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 768(2) , 267-75, (2002)

Full Text: HTML

Abstract

A sensitive and specific procedure for the simultaneous determination of dihydroergotamine (DHE) and its 8'-hydroxylated metabolite (8'-OH-DHE) in human plasma was developed and validated. The analytes were extracted from plasma samples by liquid-liquid extraction, separated through a Zorbax C18 column (50x2.1 mm I.D.) and detected by tandem mass spectrometry with an electrospray ionization interface. Caroverine was used as the internal standard. The method has a lower limit of quantitation (LOQ) of 10.0 and 11.0 pg/ml for DHE and 8'-OH-DHE, respectively. The intra- and inter-run precision was measured to be below 9.1% for both DHE and 8'-OH-DHE. The inter-run accuracy was within 4% for the analytes. The overall extraction recoveries of DHE and 8'-OH-DHE were determined to be about 58 and 52% on average, respectively. The chromatographic run time was approximately 2.5 min. More than 120 samples could be assayed daily with this method, including sample preparation, data acquisition and processing. The method developed was successfully used to investigate plasma concentrations of DHE and 8'-OH-DHE in a pharmacokinetic study of volunteers who received DHE orally.


Related Compounds

Related Articles:

Role of 5-HT1B/1Dreceptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats

2013-06-13

[Life Sci. 92(22) , 1046-54, (2013)]

Structural basis for molecular recognition at serotonin receptors.

2013-05-03

[Science 340(6132) , 610-4, (2013)]

Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog.

2008-07-01

[Br. J. Pharmacol. 154(6) , 1254-65, (2008)]

MT 300--POZEN: dihydroergotamine mesylate injection.

2003-01-01

[Drugs R. D. 4(6) , 376-7, (2003)]

Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.

1997-01-01

[Headache 37 Suppl 1 , S33-41, (1997)]

More Articles...